Last edition
News about "HER2-positive breast cancer treatment"
US FDA Approves Enhertu for New Early Breast Cancer Indications
Enhertu receives new US approvals for use before and after surgery in HER2-positive breast cancer, supported by positive DESTINY-Breast11 and DESTINY-Breast05 phase 3 trial results.
HER2-positive Breast Cancer Treatment | 18/05/2026 | By News Bureau
Henlius and Organon Win EC Nod for POHERDY, Biosimilar to PERJETA
European Commission (EC) approves Shanghai Henlius Biotech Inc. and Organon & Co.’s POHERDY (pertuzumab), the first PERJETA biosimilar in Europe, backed by strong analytical, clinical, safety, and immunogenicity data.
HER2-positive Breast Cancer Treatment | 30/04/2026 | By News Bureau | 122
DualityBio Secures China NMPA BLA Acceptance for Trastuzumab Pamirtecan in HER2+ Breast Cancer
DualityBio announces China NMPA acceptance of its BLA for trastuzumab pamirtecan, targeting unresectable or metastatic HER2-positive breast cancer in adult patients.
HER2-positive Breast Cancer Treatment | 10/04/2026 | By News Bureau | 122
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy